Former U.S. House Majority Leader Eric Cantor is selected to serve as the next president and chief executive officer (CEO) of the Pharmaceutical Research and Manufacturers of America (PhRMA), a major industry and lobbying organization representing pharmaceutical manufacturers.
Multiple outlets report the appointment as an industry leadership change that occurs at a challenging time for the sector. STAT characterizes Cantor’s start as coming during difficult conditions for the pharmaceutical industry, while other coverage focuses on his background as a former GOP House majority leader and the significance of the role at PhRMA.
The reporting is consistent on the identity of the appointee and the organization, but differs slightly in emphasis: one outlet foregrounds Cantor’s leadership timing, while others emphasize the nature of the position as a consequential lobbying job and the formal designation of Cantor as both president and CEO.
